Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.
Eur J Immunol. 2010 Mar;40(3):599-606. doi: 10.1002/eji.201040319.
Although there has been a great amount of progress in the 25 years since the first reporting of the cDNA for IL-1alpha and IL-1beta, the history of IL-1 goes back to the early 1940s. In fact, the entire field of inflammatory cytokines, TLR and the innate immune response can be found in the story of IL-1. This Viewpoint follows the steps from the identification of the fever-inducing activities of "soluble factors" produced by endotoxin-stimulated leukocytes through to the discovery of cryopyrin and the caspase-1 inflammasome and on to the clinical benefits of anti-IL-1beta-based therapeutics. It also discusses some of the current controversies regarding the activation of the inflammasome. The future of novel anti-inflammatory agents to combat chronic inflammation is based, in part, on the diseases that are uniquely responsive to anti-IL-1beta, which is surely a reason to celebrate the 25th anniversary of the cloning of IL-1alpha and IL-1beta.
尽管自首次报道白细胞介素 1α(IL-1α)和白细胞介素 1β(IL-1β)的 cDNA 以来已经取得了很大的进展,但 IL-1 的历史可以追溯到 20 世纪 40 年代初。事实上,整个炎症细胞因子、TLR 和先天免疫反应领域都可以在 IL-1 的故事中找到。本观点从鉴定内毒素刺激的白细胞产生的“可溶性因子”的发热活性开始,一直到发现冷球蛋白和半胱天冬酶-1 炎性小体,再到抗 IL-1β 治疗的临床获益,一步步展开。它还讨论了关于炎性小体激活的一些当前争议。新型抗炎药物治疗慢性炎症的未来部分基于对抗 IL-1β 有独特反应的疾病,这无疑是庆祝 IL-1α 和 IL-1β 克隆 25 周年的一个理由。